✦ LIBER ✦

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study

✍ Scribed by Wu, Yi-Long; Kim, Joo-Hang; Park, Keunchil; Zaatar, Adel; Klingelschmitt, Gaëlle; Ng, Christina

Book ID: 119320787
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 247 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.03.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of Onartuzumab

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Ervin, T. J.; Ramlau, R. A.; Daniel, D. B.; Goldschmidt, J. H.; B 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 266 KB

Phase III Trial of Vandetanib Compared W

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

✍ Natale, R. B.; Thongprasert, S.; Greco, F. A.; Thomas, M.; Tsai, C.-M.; Sunpawer 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 298 KB

88PD EFFICACY AND SAFETY OF ERLOTINIB VE

88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY

✍ Ciuleanu, T.; Stelmakh, L.; Cicenas, S.; Gonzalez, E. Esteban 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Randomized phase II study of gefitinib v

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

✍ Kim, Seung Tae; Uhm, Ji Eun; Lee, Jeeyun; Sun, Jong-mu; Sohn, Insuk; Kim, Seon W 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 359 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

22LBA Overall survival analyses from the

22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

✍ F. Cappuzzo; B. Coudert; R. Wierzbicki; K. Park; F. Custers; G.A. Curbera; G. Gi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB